The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
1210011 Informal Interpretation
20121428: G. Brint Ryan; 2003 TIL Settlement
1210004 Informal Interpretation
1210002 Informal Interpretation
1210001 Informal Interpretation
1209010 Informal Interpretation
20121360: Valeant Pharmaceuticals International, Inc.; Johnson & Johnson
20121349: John B. Zachry; J.V. Holdings
1209005 Informal Interpretation
1209004 Informal Interpretation
Novartis AG, In the Matter of (Fougera Holdings, Inc)
The FTC required drug supplier Novartis AG to give up its marketing rights to four topical skin care medications, under a settlement resolving charges that Novartis' acquisition of pharmaceutical firm Fougera Holdings, Inc. would harm competition in the market for these topical drugs. The settlement order requires Novartis to end a marketing agreement that allows it to sell three topically-applied generic drugs and return all rights to a fourth generic drug in development to its manufacturer, Tolmar, Inc. According to the FTC's complaint, Novartis' acquisition of Fougera would violate Section 5 of the FTC Act and Section 7 of the Clayton Act by reducing competition in the generic drug markets for three skin care drugs: 1) generic calcipotriene topical solution, 2) generic lidocaine-prilocaine cream, and 3) generic metronidazole topical gel. The complaint also alleges that the acquisition would eliminate potential competition in the market for the sale of diclofenac sodium gel.